USE OF OXALIPLATIN (ELOXATIN®) IN PATIENTS WITH RENAL FAILURE
- Authors: Besova N.1
-
Affiliations:
- N.N. Blokhin Russian Cancer Research Center, Russian Academy of Medical Sciences
- Issue: Vol 23, No 11 (2012)
- Pages: 35-38
- Section: Articles
- URL: https://journals.eco-vector.com/0236-3054/article/view/115555
- ID: 115555
Cite item
Abstract
Platinum drugs are widely used in oncology care. However, the use of cisplatin is limited by its nephrotoxicity that is absent in the third-generation platinum derivative oxaliplatin. There are pharmacokinetic, pharmacogenetic, and clinical data that substantiate that oxaliplatin may be prescribed for patients with insignificantly or moderately reduced kidney function (creatinine clearance > 20 ml/min).
Keywords
Full Text
About the authors
N. Besova
N.N. Blokhin Russian Cancer Research Center, Russian Academy of Medical Sciences
Email: besovans@mail.ru
Candidate of Medical Sciences Moscow
References
- Graham M., Lockwood G., Greenslade D. et al. Clinical Pharmacokinetics of Oxaliplatin. A Critical Review // Clin. Cancer Res. - 2000; 6: 1205-18.
- Takimoto C., Graham M., Lockwood G. et al. Oxaliplatin Pharmacokinetics and Pharmacodynamics in Adult Cancer Patients with Impaired Renal Function // Clin. Cancer Res. - 2007; 13: 4832-9.
- Massari C., Brienza S., Rotarski M. et al. Pharmacokinetics of oxaliplatin in patients with normal versus impaired renal function // Cancer Chemother. Pharmacol. - 2000; 45: 157-64.
- Takimoto C., Remick C., Sharma S. et al. Dose-Escalating and Pharmacological Study of Oxaliplatin in Adult Cancer Patients With Impaired Renal Function: A National Cancer Institute Organ Dysfunction Working Group Study // J. Clin. Oncol. - 2003; 21: 2664-72.
- Моисеев А. А. Фармакогенетика препаратов платины // Онкогинекология. -2012; 2: 2-12
- Burger H., Loos W., Eechoute K. et al. Drug transporters of platinum-based anticancer agents and their clinical significance // Drug. Resist. Updat. - 2011; 14: 22-34.
- Burger H., Zoumaro-Djayoon A., Boersma A. et al. Differential transport of platinum compounds by the human organic cation transporter hOCT2 (hSLC22A2) // Br. J. Pharmacol. - 2010; 159: 898-908.
- Yonezawa A., Inui K. Organic cation transporter OCT/SLC22A and H+/organic cation antiporter MATE/SLC47A are key molecules for nephrotoxicity of platinum agents // Biochem. Pharmacol. - 2011; 81: 563-8.
- Jong N., Nakanishi T., Liu J. et al. Oxaliplatin transport mediated by organic cation/carnitine transporters OCTN1 and OCTN2 in overexpressing human embryonic kidney 293 cells and rat dorsal root ganglion neurons // J. Pharmacol. Exp. Ther. - 2011; 338: 537-47.